Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results and corporate update announced for quarter ended June 30, 2026.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and corporate update announced for quarter ended June 30, 2026
- Financial details and operating developments contained in Exhibit 99.1
- Investor focus: liquidity, clinical progress, and pipeline updates in the attached release
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.